ClinicalTrials.gg
CompletedNCT01045577Updated Dec 10, 2018

A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

A Phase 2 interventional study of Masitinib and Masitinib in Psoriasis, sponsored by AB Science. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-12-10.

Sponsored by AB Science · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the activity of oral AB1010 in adults patients with moderate to severe chronic plaque psoriasis

Read the detailed description

To evaluate the activity of oral AB1010, administered at two dose levels during 12 weeks to patients with moderate to severe chronic plaque psoriasis, assessed on :

i)Body Surface Area (BSA), Psoriasis Area and Severity Index (PASI), Overall Lesion Severity (OLS), Physician's Global Assessment (PGA) and Patient's Global Psoriasis Assessment (PGPA) ii)clinical and biological safety parameters iii) pharmacokinetic profile of AB1010

02

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Severe Psoriasis
  • Kinase Inhibitor
  • Masitinib
03

In context

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

This study's enrollment of 25 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients aged 18 to 75 years with chronic plaque psoriasis
  • Plaque psoriasis covering ≥ 10% BSA
  • Disease duration ≥ 6 months
  • PASI ≥ 12.0 at screening

Exclusion criteria

Exclusion Criteria:

  • Guttate, erythrodermic or pustular psoriasis as sole or predominant form of the disease
  • psoriasis flare during screening or at time of enrollment
  • Systemic therapy for psoriasis or systemic therapy for other indications within 28 days prior to enrollment
  • Topical treatment for psoriasis within 14 days prior to enrollment
  • Use of moderate and strong inhibitors within 4 weeks prior to randomization
  • Active current bacterial, viral (including and C, , EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    Masitinib (AB1010)

    Masitinib (AB1010)

    Drug: Masitinib

  • Placebo comparator
    Placebo mactching masitinib

    Placebo matching masitinib

    Drug: Placebo

Interventions

  • 6 mg/kg/day

  • 3 mg/kg/day

  • DrugPlacebo

    Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)

06

What researchers measure

Primary outcomes

  1. Change from baseline in BSA after 12 weeks of treatment

    Time frame: 12 weeks

Secondary outcomes

  1. Percentage change from baseline in PASI score, proportion of patients reaching a 90%, 75% or 50% improvement in PASI score after 12 weeks of treatment; time to and duration of first occurrence in PASI 50, 75 and 90

    Time frame: 12 weeks

  2. Proportion of patients achieving an OLS rating of Minimal or Clear after 12 weeks

    Time frame: 12 weeks

  3. Percentage change from baseline in PGA and PGPA after 12 weeks of treatment

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Jan 2006 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2010
First posted
Jan 11, 2010
Start
Sep 2005
Primary completionActual
Jan 2006
CompletionActual
Feb 2008
Last update
Dec 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01045577
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Jan 11, 2010
Start date
Sep 2005
Primary completion
Jan 2006
Completion
Feb 2008
Last update
Dec 10, 2018

Study contacts

Jean-Paul ORTONNE, MD
principal investigator · CHU Nice

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion